Occurrence of impaired fasting glucose in GH‐deficient adults receiving GH replacement compared with untreated subjects
(2010) In Clinical Endocrinology 72(1). p.59-69- Abstract
- Objective: The effects of GH replacement on glucose metabolism in GH-deficient (GHD) adults in clinical practice are not well defined. Therefore, we assessed GH treatment effects on fasting plasma glucose (FPG) and haemoglobin A1c (A1c) concentrations in GHD adults in a clinical setting.
Design: Post-hoc analysis of the observational Hypopituitary Control and Complications Study conducted at 157 US centres (1997-2002).
Patients: GH-deficient adults who were GH-naïve at study entry and had at least two FPG measurements.
Measurements: Effect of GH treatment on the frequency and time course of abnormal FPG (> or =5.6 mmol/l) development, FPG normalization, progression of increased FPG and abnormal follow-up A1c (>6%) values... (More) - Objective: The effects of GH replacement on glucose metabolism in GH-deficient (GHD) adults in clinical practice are not well defined. Therefore, we assessed GH treatment effects on fasting plasma glucose (FPG) and haemoglobin A1c (A1c) concentrations in GHD adults in a clinical setting.
Design: Post-hoc analysis of the observational Hypopituitary Control and Complications Study conducted at 157 US centres (1997-2002).
Patients: GH-deficient adults who were GH-naïve at study entry and had at least two FPG measurements.
Measurements: Effect of GH treatment on the frequency and time course of abnormal FPG (> or =5.6 mmol/l) development, FPG normalization, progression of increased FPG and abnormal follow-up A1c (>6%) values in GHD patients treated with GH (n = 403) or untreated (n = 169) at their physician's discretion.
Results: In subjects without pre-existing diabetes mellitus, development of an abnormal FPG tended to occur in a greater percentage of GH-treated than untreated subjects (35.3% versus 24.5, P = 0.06). Additionally, GH treatment was associated with a mild, transient increase in FPG and shorter time to development of an abnormal FPG in these subjects (P < 0.01). Most ( approximately 80%) abnormal FPG values were below 7 mmol/l and normalized in 69% of GH-treated subjects without diabetes. Treatment with GH had no effect on the rate of FPG normalization, progression of increased FPG or abnormal follow-up A1c values.
Conclusions: Initiation of GH replacement in GHD adults was associated with a mild increase in FPG that often normalized spontaneously. Nevertheless, clinicians should monitor FPG in patients receiving GH treatment.
(Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/b7312ab8-11df-45a2-8879-9f9dda7f5565
- author
- Woodmansee, Whitney w. ; Hartman, Mark l. ; Lamberts, Steven w.j. ; Zagar, Anthony j. and Clemmons, David r.
- contributor
- Erfurth, Eva Marie LU
- author collaboration
- publishing date
- 2010-01-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical Endocrinology
- volume
- 72
- issue
- 1
- pages
- 59 - 69
- publisher
- Wiley-Blackwell
- external identifiers
-
- scopus:72249117360
- ISSN
- 1365-2265
- DOI
- 10.1111/j.1365-2265.2009.03612.x
- language
- English
- LU publication?
- no
- id
- b7312ab8-11df-45a2-8879-9f9dda7f5565
- date added to LUP
- 2023-11-14 13:00:23
- date last changed
- 2023-11-15 04:02:07
@article{b7312ab8-11df-45a2-8879-9f9dda7f5565, abstract = {{Objective: The effects of GH replacement on glucose metabolism in GH-deficient (GHD) adults in clinical practice are not well defined. Therefore, we assessed GH treatment effects on fasting plasma glucose (FPG) and haemoglobin A1c (A1c) concentrations in GHD adults in a clinical setting.<br/>Design: Post-hoc analysis of the observational Hypopituitary Control and Complications Study conducted at 157 US centres (1997-2002).<br/>Patients: GH-deficient adults who were GH-naïve at study entry and had at least two FPG measurements.<br/>Measurements: Effect of GH treatment on the frequency and time course of abnormal FPG (> or =5.6 mmol/l) development, FPG normalization, progression of increased FPG and abnormal follow-up A1c (>6%) values in GHD patients treated with GH (n = 403) or untreated (n = 169) at their physician's discretion.<br/>Results: In subjects without pre-existing diabetes mellitus, development of an abnormal FPG tended to occur in a greater percentage of GH-treated than untreated subjects (35.3% versus 24.5, P = 0.06). Additionally, GH treatment was associated with a mild, transient increase in FPG and shorter time to development of an abnormal FPG in these subjects (P < 0.01). Most ( approximately 80%) abnormal FPG values were below 7 mmol/l and normalized in 69% of GH-treated subjects without diabetes. Treatment with GH had no effect on the rate of FPG normalization, progression of increased FPG or abnormal follow-up A1c values.<br/>Conclusions: Initiation of GH replacement in GHD adults was associated with a mild increase in FPG that often normalized spontaneously. Nevertheless, clinicians should monitor FPG in patients receiving GH treatment.<br/>}}, author = {{Woodmansee, Whitney w. and Hartman, Mark l. and Lamberts, Steven w.j. and Zagar, Anthony j. and Clemmons, David r.}}, issn = {{1365-2265}}, language = {{eng}}, month = {{01}}, number = {{1}}, pages = {{59--69}}, publisher = {{Wiley-Blackwell}}, series = {{Clinical Endocrinology}}, title = {{Occurrence of impaired fasting glucose in GH‐deficient adults receiving GH replacement compared with untreated subjects}}, url = {{http://dx.doi.org/10.1111/j.1365-2265.2009.03612.x}}, doi = {{10.1111/j.1365-2265.2009.03612.x}}, volume = {{72}}, year = {{2010}}, }